Table 2.
Drug/input | Cost (€) | Unit |
---|---|---|
Drug acquisition costs a | ||
SEC 150 mg | 584.43 | Per dose |
SEC 300 mg | 1168.86 | Per dose |
CER P 200 mg | 483.07 | Per prefilled syringe |
ETN 50 mg | 260.04 | Per prefilled syringe |
ADA 40 mg | 527.41 | Per prefilled syringe |
INF 100 mg | 436.06 | Per vial |
GOL 50 mg | 1086.93 | Per prefilled syringe |
UST 45/90 mg | 3124.96 | Per prefilled syringe |
APR 10–30 mg | 418.52 | Per 14 day pack |
APR 30 mg | 14.93 | Per tablet |
ETN biosimilar 50 mg | 182.02 | Per prefilled syringe |
ADA biosimilar 40 mg | 369.19 | Per prefilled syringe |
MTX 7.5 mg | 0.51 | Per dose |
Disease-related costs | ||
Intercept | 297.89 | Per 3 months |
Cost per HAQ change | 131.61 | Per 1-unit change per 3-months |
Health states | ||
Uncontrolled psoriasis (PASI < 75) | 253.14 | Per 3 months |
Controlled psoriasis (PASI ≥ 75) | 20.46 | Per 3 months |
ADA, adalimumab; APR, apremilast; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; HAQ, Health Assessment Questionnaire; INF, infliximab; LEF, leflunomide; MTX, methotrexate; PASI, Psoriasis Area Severity Index; SEC, secukinumab; SUL, sulfasalazine; UST, ustekinumab
Source: Costs from the York model (Rodgers et al., [28]) who extracted costs from the following sources. Cost for a 1-point change in HAQ obtained from Kobelt et al. [49]. Cost for uncontrolled psoriasis obtained from Department of Health [50]. Cost for controlled psoriasis obtained from Hartman et al. [51]
aFinnish medicinal products and prices database [accessed on-line 2.1.2018]. All prices exclude value added tax. Retail price for SC products, and wholesale price for IV products is applied according to local guidelines. Infliximab price is weighed with market share. A cost of €382 (2016 value) is added for each IV administration [48] Biosimilar pricing for etanercept and adalimumab assumed to be 30% less than brand; they were not available in the market at the time of analyses, and thus only used for sensitivity analysis